In the News

386 News Items found
Memorial Sloan Kettering medical oncologist Santosha Vardhana with medical mask on.
MSK experts acted quickly to understand the possible effects of COVID-19 on cancer patients and drew on vast experience to explore new treatments.
Participants in Cycle for Survival
Treating Rare Cancers
Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact [email protected].
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
MSK scientists Andrew Kung and Elli Papaemmanuil
By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Samuel Danishefsky
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
Jedd Wolchok and Charlotte Ariyan in the lab
In the Clinic
A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.
An MSK scientist pipettes in the lab
MSK Research Highlights, May 18, 2023
New MSK research shows how high-risk neuroblastoma evolves to be so deadly; finds continued safety and efficacy for sotorasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer; and demonstrates promise in eradicating tumors by delivering a viral-based immunotherapeutic to melanoma and breast cancer in mouse models.
Pictured: Jedd Wolchok and James Allison
In the News
In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan Kettering Institute's Immunology Program, and medical oncologist and immunologist Jedd Wolchok.
Albert Kuchler with MSK medical oncologist Bob Li.
Computational biology is helping to bring predictive power and precision to oncology.